Understanding disparities for those with severe mental illness, particularly those with schizophrenia, is essential as these individuals have the most difficulty navigating the U.S. health care system. Schizophrenia is chronic, associated with substantial disability, and poses a large burden to society, with minorities bearing a larger share of this burden in the U.S. Although there is some evidence of black-white disparities in quality of schizophrenia care, little research is available for Latinos or about temporal trends. We do not know whether geographic variation in patterns of care contribute to disparities;nor do we know the role of characteristics of the communities where patients live in disparities. This proposal seeks to detect and understand disparities for black and Latino Medicaid beneficiaries with schizophrenia using longitudinal data from four racially/ethnically and geographically diverse states.
We aim to (1) assess disparities in quality of care and to systematically estimate the contribution of county-level factors to disparities;(2) assess disparities in diffusion rates of innovative treatments and to systematically estimate the contribution of county-level factors to disparities;and (3) investigate policies associated with equity through detailed interviews with policy-makers and other key individuals based at high- and low-performing counties identified in Aim (1). By gathering evidence of the contextual factors associated with disparities, we will provide concrete targets for reform, priorities for resource allocation, and policy levers in the service of equity.

Public Health Relevance

The proposed research has public health relevance because in addition to documenting the existence of health care disparities for publicly insured people with schizophrenia we seek to elucidate contextual factors associated with disparities at the local level. This kind of granular knowledge can be extremely valuable to public policy efforts aimed at improving quality and equity of care.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
3R01MH087488-03S1
Application #
8519860
Study Section
Mental Health Services in Non-Specialty Settings (SRNS)
Program Officer
Chambers, David A
Project Start
2010-09-08
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$378,301
Indirect Cost
$129,875
Name
Rand Corporation
Department
Type
DUNS #
006914071
City
Santa Monica
State
CA
Country
United States
Zip Code
90401
Mulcahy, Andrew W; Normand, Sharon-Lise; Newcomer, John W et al. (2017) Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics. Psychiatr Serv 68:1280-1287
Huskamp, Haiden A; Horvitz-Lennon, Marcela; Berndt, Ernst R et al. (2016) Patterns of Antipsychotic Prescribing by Physicians to Young Children. Psychiatr Serv 67:1307-1314
Horvitz-Lennon, Marcela; Volya, Rita; Garfield, Rachel et al. (2015) Where You Live Matters: Quality and Racial/Ethnic Disparities in Schizophrenia Care in Four State Medicaid Programs. Health Serv Res 50:1710-29
Horvitz-Lennon, Marcela; Volya, Rita; Donohue, Julie M et al. (2014) Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008. Health Serv Res 49:1121-44
Donohue, Julie; O'Malley, A James; Horvitz-Lennon, Marcela et al. (2014) Changes in physician antipsychotic prescribing preferences, 2002-2007. Psychiatr Serv 65:315-22
Huskamp, Haiden A; O'Malley, A James; Horvitz-Lennon, Marcela et al. (2013) How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. Psychiatr Serv 64:324-30
Horvitz-Lennon, Marcela; Donohue, Julie M; Lave, Judith R et al. (2013) The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries. Psychiatr Serv 64:230-7
Horvitz-Lennon, Marcela; Alegría, Margarita; Normand, Sharon-Lise T (2012) The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia. Psychiatr Serv 63:1171-7